Aldesleukin

CHEMBL1201438 Phase 4 Đã phê duyệt Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A laboratory-made version of interleukin-2, a natural immune system protein that stimulates the growth and activity of T cells and natural killer cells to attack cancer. It is used as an immunotherapy for advanced kidney cancer and melanoma, activating the body's own immune defenses to fight tumor cells.

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A laboratory-made version of interleukin-2, a natural immune system protein that stimulates the growth and activity of T cells and natural killer cells to attack cancer. It is used as an immunotherapy for advanced kidney cancer and melanoma, activating the body's own immune defenses to fight tumor cells.

Yes, Aldesleukin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201438. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.